Ayesheh Enayati

Ayesheh Enayati

Auto-generated profile, based on publicly available information

Ayesheh Enayati

Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2023 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
AEAyesheh Enayati
Ayesheh Enayati
ASAida Soghi
Aida Soghi
ABAlexandra E Butler
Alexandra E Butler
MRManfredi Rizzo
Manfredi Rizzo
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Ayesheh Enayati, Aida Soghi, Alexandra E Butler, Manfredi Rizzo, and Amirhossein Sahebkar. J Neurogastroenterol Motil 2023;29:409-18. https://doi.org/10.5056/jnm23065

1 February 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AEAyesheh Enayati
Ayesheh Enayati
TJThomas P. Johnston
Thomas P. Johnston
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Cardiovascular diseases are the leading cause of death in the world. Atherosclerosis is characterized by oxidized lipid deposition and inflammation in the arterial wall and represents a significant problem in public health and medicine. Some dietary spices have been widely used in many countries; however, the mechanism of their action as it relates to the prevention and treatment of atherosclerosis is still poorly understood. In this review, we focus on the properties of various spice-derived active ingredients used in the prevention and treatment of atherosclerosis, as well as associated atherosclerotic risk factors. We provide a summary of the mechanisms of action, epidemiological analyses, and studies of various components of spice used in the clinic, animal models, and cell lines related to atherosclerosis. Most notably, we focused on mechanisms of action by which these spice-derived compounds elicit their lipid-lowering, anti-inflammatory, antioxidant, and immunomodulatory properties, as well as their involvement in selected biochemical and signal transduction pathways. It is suggested that future research should aim to design well-controlled clinical trials and more thoroughly investigate the role of spices and their active components in the prevention/treatment of atherosclerosis. Based on this literature review, it appears that spices and their active components are well tolerated and have few adverse side effects and, therefore, provide a promising adjunctive treatment strategy for patients with atherosclerosis.

1 February 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HMHamid Reza Moheimani
Hamid Reza Moheimani
TATaghi Amiriani
Taghi Amiriani
AAAli Mohammad Alizadeh
Ali Mohammad Alizadeh
YJYahya Jand
Yahya Jand
DSDelaram Shakiba
Delaram Shakiba
VKVahid Khori
Vahid Khori

26 November 2021 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
AEAyesheh Enayati
Ayesheh Enayati
ASAref Salehi
Aref Salehi
MAMostafa Alilou
Mostafa Alilou
HSHermann Stuppner
Hermann Stuppner
MPMirali Polshekan
Mirali Polshekan
VKVahid Khori
Vahid Khori
Background: Our previous study indicated that Potentilla reptans root has a preconditioning effect by its antioxidant and anti-apoptotic effects in an isolated rat heart ischemia/reperfusion (IR) model. In the present study, we investigated the post-conditioning cardio-protective effects of Potentilla reptans and its active substances. Methods: The ethyl acetate fraction of P. reptans root (Et) was subjected to an IR model under 30 min of ischemia and 100 min of reperfusion. To investigate the postconditioning effect, Et was perfused for 15 min at the early phase of reperfusion. RISK/SAFE pathway inhibitors, 5HD and L-NAME, were applied individually 10 min before the ischemia, either alone or in combination with Et during the early reperfusion phase. The hemodynamic factors and ventricular arrhythmia were calculated during the reperfusion. Oxidative stress, apoptosis markers, GSK-3β and SGK1 proteins were assessed at the end of experiments. Results: Et postconditioning (Etpost) significantly reduced the infarct size, arrhythmia score, ventricular fibrillation incidence, and enhanced the hemodynamic parameters by decreasing the MDA level and increasing expression of Nrf2, SOD and CAT activities. Meanwhile, Etpost increased the BCl-2/BAX ratio and decreased Caspase-3 expression. The cardioprotective effect of Etpost was abrogated by L-NAME, Wortmannin (a PI3K/Akt inhibitor), and AG490 (a JAK/STAT3 inhibitor). Finally, Etpost reduced the expression of GSK-3β and SGK1 proteins pertaining to the IR group. Conclusion: P. reptans reveals the post-conditioning effects via the Nrf2 pathway, NO release, and the RISK/SAFE pathway. Also, Etpost decreased apoptotic indexes by inhibiting GSK-3β and SGK1 expressions. Hence, our data suggest that Etpost can be a suitable natural candidate to protect cardiomyocytes during reperfusion injury.

29 August 2023 in Archiv der Pharmazie
Verified
Journal Article
Closed access
SNSoraya Noorgaldi
Soraya Noorgaldi
HSHamzeh Badeli Sarkala
Hamzeh Badeli Sarkala
AEAyesheh Enayati
Ayesheh Enayati
VKVahid Khori
Vahid Khori
Gökhan ZenginGökhan Zengin
Gökhan Zengin
MJMehrdad Jahanshahi
Mehrdad Jahanshahi

22 February 2025 in Anesthesiology and Pain Medicine
Verified
Journal Article
Open access
PDF file
BHBassim Mohammed Jabbar Hatemi
Bassim Mohammed Jabbar Hatemi
AEAyesheh Enayati
Ayesheh Enayati
SGSomayeh Ghorbani
Somayeh Ghorbani
FTFatemeh Tahmasebi
Fatemeh Tahmasebi
HAHadi Abo Aljadayel
Hadi Abo Aljadayel
AMAli Movafegh
Ali Movafegh
Background: This study aimed to assess the collateral effects and safety of dexmedetomidine (Dex) during and one day after surgery in Iranian patients undergoing open heart surgery, to expand the clinical applications of Dex in Iran. Methods: This pilot study was conducted in Gorgan, Golestan province, Iran, in 2024. Both male and female participants undergoing open heart surgery were randomly assigned to either the Dex group (n = 10), receiving 0.5 µg/kg/h along with standard anesthesia management, or the control group (n = 10). The primary outcome was the percentage of patients experiencing adverse events. Secondary outcomes included the stability of hemodynamic and respiratory parameters, the occurrence of arrhythmias, and biological changes assessed during and 24 hours after surgery. Results: Out of 45 participants, 20 were enrolled and analyzed. The comparison between groups showed that observed adverse effects were higher in the control group (4 patients) compared to the Dex group (1 patient), with common events being hypotension, bradycardia, and tachycardia. Biological markers, such as lactate and blood sugar (BS), increased in both groups, with the control group showing a greater increase in both lactate and BS levels (P = 0.012 and P = 0.009, respectively) compared to the Dex group (P = 0.017 and P = 0.093, respectively). Additionally, there were no significant differences in hemodynamic and respiratory markers between the groups (P > 0.05); however, Dex improved and preserved hemodynamic and respiratory stability more effectively. Conclusions: The addition of Dex to the anesthesia protocol was safe and without adverse events, showing a promising role in improving cardiac function in patients undergoing open heart surgery.